Equities research analysts expect Horizon Pharma PLC (NASDAQ:HZNP) to report $236.80 million in sales for the current quarter, Zacks reports. Three analysts have issued estimates for Horizon Pharma’s earnings. The highest sales estimate is $247.63 million and the lowest is $230.27 million. Horizon Pharma reported sales of $223.88 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 5.8%. The company is scheduled to announce its next quarterly earnings results on Wednesday, May 8th.
On average, analysts expect that Horizon Pharma will report full-year sales of $1.24 billion for the current year, with estimates ranging from $1.24 billion to $1.25 billion. For the next financial year, analysts forecast that the company will post sales of $1.39 billion, with estimates ranging from $1.35 billion to $1.44 billion. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Horizon Pharma.
Horizon Pharma (NASDAQ:HZNP) last posted its earnings results on Wednesday, February 27th. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.54 by $0.13. The company had revenue of $355.50 million during the quarter, compared to analyst estimates of $334.22 million. Horizon Pharma had a positive return on equity of 34.09% and a negative net margin of 6.34%. The company’s revenue for the quarter was up 29.6% compared to the same quarter last year. During the same period in the previous year, the company earned $0.29 EPS.
Horizon Pharma stock opened at $27.66 on Tuesday. The stock has a market cap of $4.73 billion, a PE ratio of 15.11, a P/E/G ratio of 1.49 and a beta of 1.16. Horizon Pharma has a 1 year low of $12.55 and a 1 year high of $29.44. The company has a debt-to-equity ratio of 1.80, a current ratio of 2.03 and a quick ratio of 1.97.
In other news, EVP Geoffrey M. Curtis sold 10,080 shares of Horizon Pharma stock in a transaction dated Monday, February 25th. The stock was sold at an average price of $21.21, for a total transaction of $213,796.80. Following the transaction, the executive vice president now owns 35,367 shares in the company, valued at approximately $750,134.07. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Geoffrey M. Curtis sold 8,835 shares of Horizon Pharma stock in a transaction dated Tuesday, February 5th. The shares were sold at an average price of $23.15, for a total value of $204,530.25. Following the transaction, the executive vice president now owns 32,202 shares in the company, valued at approximately $745,476.30. The disclosure for this sale can be found here. Insiders own 3.90% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HZNP. Scopia Capital Management LP lifted its stake in Horizon Pharma by 23.9% in the 3rd quarter. Scopia Capital Management LP now owns 14,762,354 shares of the biopharmaceutical company’s stock valued at $289,047,000 after acquiring an additional 2,850,064 shares in the last quarter. Norges Bank bought a new stake in Horizon Pharma in the 4th quarter valued at approximately $46,493,000. FMR LLC lifted its stake in Horizon Pharma by 361.8% in the 4th quarter. FMR LLC now owns 1,963,146 shares of the biopharmaceutical company’s stock valued at $38,360,000 after acquiring an additional 1,538,056 shares in the last quarter. Jennison Associates LLC bought a new stake in Horizon Pharma in the 3rd quarter valued at approximately $27,670,000. Finally, D. E. Shaw & Co. Inc. lifted its stake in Horizon Pharma by 63.8% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 3,369,508 shares of the biopharmaceutical company’s stock valued at $65,840,000 after acquiring an additional 1,312,142 shares in the last quarter. Hedge funds and other institutional investors own 88.83% of the company’s stock.
About Horizon Pharma
Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
See Also: What is the Coverage Ratio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.